Skip to main content
Nuclear medicine

Nuclear medicine

MILabs’ VECTor6 awarded ‘Commercial Innovation of the Year’ at WMIC

19 Sep 2018 Tami Freeman
MILabs’ VECTor6
MILabs’ VECTor6 preclinical imaging system

MILabs, a Dutch developer of molecular imaging systems, has received the “Commercial Innovation of the Year” award at the recent World Molecular Imaging Congress (WMIC) in Seattle, WA. The award was presented for the company’s VECTor6 preclinical imaging system with its new broadband photon tomography technique.

The VECTor6 system advances state-of-the-art PET imaging by increasing PET resolution down to 0.55 mm for 18F and eliminating positron range effects for PET isotopes such as 124I and 82Rb. Moreover, the system can image multiple PET isotopes simultaneously and obtain both spatial and temporal co-registered PET/SPECT and PET/radiotherapy images, including those of all alpha- and beta-isotopes used in theranostics.

The VECTor6 also incorporates best-in-class in vivo optical and X-ray CT modalities, enabling nuclear and optical molecular imaging to be performed on a single platform. By imaging a photon energy range from 1 eV to 1 MeV, MILabs expects its broadband photon tomography technique will extend the applications of in vivo animal imaging far beyond the capabilities of current preclinical imaging systems.

“We are very encouraged that the molecular imaging community, including opinion leaders as well as industry peers, have recognized the technological innovations incorporated in our latest product, the VECTor6 system,” says Frederik Beekman, CEO/CSO of MILabs. “Especially for PET imaging, this product pushes the boundaries of performance beyond the limits of current preclinical systems.”

Copyright © 2024 by IOP Publishing Ltd and individual contributors